Bydureon and Byetta: What Happened to the First GLP-1 Drugs

Long before anyone was talking about Ozempic, there was Byetta.

It reached US pharmacies in 2005 as the first GLP-1 receptor agonist ever approved — a twice-daily injection for type 2 diabetes that did something no diabetes pill had done, which was help people lose weight rather than gain it. Seven years later its once-weekly successor, Bydureon, arrived and made weekly dosing possible for the first time.

Both are now gone. AstraZeneca stopped marketing them in October 2024, and the FDA formally withdrew their approvals effective September 3, 2025 [1].

If you or a family member took one of these, this article explains what happened, why, and what exists now. If you are just curious how the class that produced Ozempic and Mounjaro actually began, that story is here too.

Nothing in this article is medical advice. Where it describes how a drug was dosed, it is summarizing the FDA-approved prescribing information and Instructions for Use for a product, as a matter of record; the schedule that applies to anyone taking exenatide today is the one on their own prescription. If your medicine was discontinued, that is a conversation with a healthcare provider, not something to solve from a web page.

Where did exenatide come from?

From a lizard, which is not a joke.

In 1992, researchers isolated a peptide they called exendin-4 from the venom of Heloderma suspectum, the Gila monster, and reported that it acted on receptors in the pancreas and raised cellular cAMP [2]. Exendin-4 turned out to resemble human GLP-1 closely enough to activate the same receptor, but with a structure that human enzymes could not break down nearly as fast. Natural human GLP-1 has a half-life measured in minutes. That was the whole problem: the hormone worked, but it vanished too quickly to be a drug.

Exenatide is a synthetic copy of exendin-4. Amylin Pharmaceuticals and Eli Lilly developed it together, and it was approved in the US in 2005 as Byetta, a 5 mcg and 10 mcg prefilled pen injected twice a day within 60 minutes before the morning and evening meals.

The corporate chain that followed is worth knowing, because it explains why an AstraZeneca notice ended a Lilly-era product. Bristol-Myers Squibb acquired Amylin in 2012. AstraZeneca took full ownership of the exenatide franchise from BMS in 2014. AstraZeneca also inherited the pramlintide product Symlin from the same Amylin heritage — and that line is winding down too: its SymlinPen entries in the FDA National Drug Code directory carry marketing end dates of January 31, 2027 (checked September 14, 2026) [12].

What was Bydureon, and how was it different?

Bydureon was the same molecule packaged to last a week. Exenatide was embedded in slowly dissolving polymer microspheres, so a single 2 mg injection released drug gradually over days instead of hours.

It was approved on January 27, 2012 — the first once-weekly GLP-1 anywhere — and it was genuinely hard to use at first. The original version required mixing a powder with a diluent before each injection. A pen version followed, and then on October 20, 2017 the FDA approved Bydureon BCise, an autoinjector that arrived premixed and made the whole thing much simpler.

The microsphere technology came with two real costs. Injection-site nodules were common, because the polymer spheres sat under the skin while they dissolved. And extended-release exenatide was immunogenic: a substantial minority of patients developed anti-exenatide antibodies, which is not something the human GLP-1 analogs run into to the same degree.

Why did exenatide lose?

Three things happened, in order.

It lost a head-to-head trial. DURATION-6 randomized 911 adults with type 2 diabetes to once-weekly exenatide 2 mg or once-daily liraglutide 1.8 mg for 26 weeks. A1C fell 1.28 percentage points on exenatide and 1.48 on liraglutide. The 0.21 point difference favored liraglutide, and exenatide failed to meet the trial’s predefined noninferiority criteria [3].

The trial did show one advantage for exenatide: it was easier to tolerate. Nausea occurred in 9 percent of the exenatide group versus 21 percent on liraglutide, diarrhea in 6 percent versus 13 percent [3]. Weekly dosing plus fewer side effects is a real selling point, but it turned out not to be enough when the competitor worked better.

It missed on the heart. EXSCEL was the largest GLP-1 cardiovascular outcomes trial ever run by enrollment — 14,752 patients followed for a median of 3.2 years. The primary outcome occurred in 11.4 percent of the exenatide group versus 12.2 percent on placebo, a hazard ratio of 0.91 with a 95 percent confidence interval of 0.83 to 1.00 and a p value of 0.06 for superiority [4].

That is about as close as a trial can come without counting. Exenatide was shown to be cardiovascularly safe, but it never earned a cardiovascular indication. Meanwhile liraglutide’s LEADER trial and dulaglutide’s REWIND trial both succeeded, and both drugs got indications that exenatide could not match.

Then semaglutide arrived, and later tirzepatide, and the gap widened from a fraction of an A1C point to something much larger.

By the early 2020s, exenatide was a drug that was harder to inject, less effective, and carried no heart claim, competing against weekly injections that were better on every measure.

What exactly did the FDA withdrawal mean?

This part causes confusion, so it is worth being precise.

On August 4, 2025 the FDA published a Federal Register notice, 90 FR 36440, withdrawing approval of 39 new drug applications. Three of them were AstraZeneca’s exenatide products: Byetta under NDA 021773, Bydureon and Bydureon Pen under NDA 022200, and Bydureon BCise under NDA 209210. The withdrawals took effect September 3, 2025 [1].

The notice states that these withdrawals happened at the applicants’ own request, under 21 CFR 314.150(c), the regulation covering voluntary withdrawal, because the products were no longer marketed. It is explicitly not a safety or effectiveness action, and it is without prejudice to refiling. The notice also said product already in inventory on September 3, 2025 could continue to be dispensed until it was used up or expired [1].

In plain terms: the company stopped selling them, then asked the FDA to close the paperwork. Nobody found a problem with the drug.

What happened to patients who were on them?

They were moved, and mostly not by choice.

UnitedHealthcare’s provider notice of December 19, 2024 is the clearest public record of how a large payer handled it. It told prescribers the products were being discontinued and listed the GLP-1s that remained preferred on its commercial plans at that time — Mounjaro, Ozempic, Rybelsus, Trulicity and liraglutide — with a shorter list on its ACA marketplace plans [5].

The two groups of patients had very different experiences:

People on twice-daily Byetta had a same-molecule option. The FDA approved the first generic referencing Byetta on November 19, 2024, under ANDA 206697 held by Amneal, and the product’s FDA listing records marketing beginning November 22, 2024 [6][12]. It copies the 5 mcg and 10 mcg pens and is approved only for type 2 diabetes, not for weight management.

People on weekly Bydureon BCise had nothing equivalent. No generic weekly exenatide exists, and none is in sight. Everyone on that product had to change molecules, restart an escalation ladder on a new drug, and go through whatever prior authorization their plan required.

Is generic exenatide worth it?

It depends what you are comparing it to.

Generic exenatide’s National Average Drug Acquisition Cost — the survey-based average price US retail pharmacies pay — was $300.17 per milliliter in July 2026. The last recorded NADAC for brand Byetta was $340.10 per milliliter in February 2025 [7]. That is roughly a 12 percent discount, which is not what most people picture when they hear the word “generic.”

For context, generic liraglutide for type 2 diabetes was $32.00 per milliliter for the three-pack, effective August 19, 2026 [7] — about a ninth of the cost per milliliter, for a drug that beat exenatide in a head-to-head trial and carries a cardiovascular indication.

Those are pharmacy acquisition costs, not patient prices, and they ignore rebates and copays. But the comparison explains why generic exenatide is a niche product rather than a comeback.

Whatever happened to exenatide for Parkinson’s disease?

For several years, exenatide was one of the more exciting repurposing stories in neurology. Small earlier studies suggested GLP-1 signaling might slow the progression of Parkinson’s disease, and a UK phase 3 trial was launched to find out.

Exenatide-PD3 randomized 194 people to once-weekly exenatide or placebo for 96 weeks. It found no benefit. The movement-disorder rating scale score worsened by 5.7 points in the exenatide group and 4.5 points on placebo, with an adjusted coefficient of 0.92 and a p value of 0.47 [8].

There is an important complication. On June 22, 2026 the editors of The Lancet issued an Expression of Concern about the published paper [9]. As of September 2026 the paper had not been retracted. An Expression of Concern is a flag, not a verdict, and it means the published record on this trial should be treated as unsettled and checked for updates rather than cited as final.

What does this story tell you about the rest of the class?

Three durable lessons.

Being first does not protect you. Byetta created this market. It is gone, and the companies that own the top-selling drugs in the class today were not the ones that started it.

Cardiovascular outcomes trials reshaped the class. Liraglutide and dulaglutide got indications and stayed. Exenatide and lixisenatide did not and left. Albiglutide’s trial was positive but reported after GSK had already withdrawn the drug — good data arriving too late to matter.

A discontinuation can force a switch that no trial would have recommended. Nobody studied moving Bydureon patients onto a specific replacement. They were moved onto whatever their formulary preferred.

If you are on an older GLP-1 today and wondering whether the same thing could happen to you: Saxenda is already scheduled for discontinuation with last shipments in late January 2027, and the Rybelsus name was retired in the US in 2026 when oral semaglutide moved under the Ozempic brand. The FDA publishes discontinuation and shortage lists, and manufacturers generally give notice. The practical move is to raise it at a routine appointment rather than when the pharmacy tells you they cannot fill it.

Sources

1. Withdrawal of Approval of 39 New Drug Applications, Federal Register, August 4, 2025
2. Exendin-4, a new peptide from Heloderma suspectum venom, potentiates cholecystokinin-induced amylase release from rat pancreatic acini, Regulatory Peptides, 1992
3. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6), The Lancet, 2013
4. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (EXSCEL), New England Journal of Medicine, 2017
5. Discontinuation of Bydureon BCise and Byetta, UnitedHealthcare, December 19, 2024
6. 2024 First Generic Drug Approvals (ANDA 206697, exenatide injection, approved November 19, 2024), US Food and Drug Administration
7. NADAC (National Average Drug Acquisition Cost), Centers for Medicare & Medicaid Services
8. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson’s disease in the UK (Exenatide-PD3), The Lancet, published online February 4, 2025
9. Expression of Concern: Exenatide once a week versus placebo … in the UK, The Lancet, published online June 22, 2026 (doi 10.1016/S0140-6736(26)01241-9)
10. Exenatide-PD3 study record, ClinicalTrials.gov
11. Exenatide labels, DailyMed, National Library of Medicine
12. National Drug Code Directory, US Food and Drug Administration, openFDA (exenatide ANDA 206697 marketing start date 2024-11-22; checked September 14, 2026)